Harbor Investment Advisory LLC Buys 712 Shares of AstraZeneca PLC (NASDAQ:AZN)

Harbor Investment Advisory LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 36.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,665 shares of the company’s stock after buying an additional 712 shares during the quarter. Harbor Investment Advisory LLC’s holdings in AstraZeneca were worth $175,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. grew its holdings in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter valued at approximately $28,000. Groupama Asset Managment grew its holdings in AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in AstraZeneca in the 3rd quarter valued at approximately $45,000. Finally, Versant Capital Management Inc grew its holdings in AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after buying an additional 707 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN stock opened at $68.20 on Thursday. The stock’s fifty day simple moving average is $66.20 and its 200 day simple moving average is $74.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market cap of $211.49 billion, a price-to-earnings ratio of 32.63, a P/E/G ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.87 EPS. On average, analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AZN has been the topic of several recent research reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.